Johnson & Johnson $JNJ Shares Bought by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 207,929 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Johnson & Johnson makes up 0.6% of Oregon Public Employees Retirement Fund’s portfolio, making the stock its 21st biggest position. Oregon Public Employees Retirement Fund’s holdings in Johnson & Johnson were worth $31,761,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in JNJ. Brighton Jones LLC grew its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the 1st quarter valued at $218,000. GAMMA Investing LLC grew its holdings in Johnson & Johnson by 48.0% during the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock valued at $7,215,000 after purchasing an additional 14,118 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Johnson & Johnson by 6.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company’s stock valued at $281,734,000 after acquiring an additional 107,009 shares during the last quarter. Finally, Stephens Consulting LLC boosted its stake in Johnson & Johnson by 13.8% during the 1st quarter. Stephens Consulting LLC now owns 4,714 shares of the company’s stock valued at $782,000 after acquiring an additional 571 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Sanford C. Bernstein increased their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research note on Monday, October 6th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. HSBC raised their price target on shares of Johnson & Johnson from $188.00 to $210.00 in a research report on Tuesday, September 30th. Finally, Bank of America raised their price target on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $199.59.

Johnson & Johnson Stock Up 0.1%

JNJ stock opened at $190.96 on Thursday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The firm’s 50-day simple moving average is $179.68 and its 200 day simple moving average is $164.34. The stock has a market cap of $459.90 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The business had revenue of $24.02 billion for the quarter. As a group, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.